Department of General Surgery, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Department of General Surgery, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
J Surg Res. 2024 Apr;296:556-562. doi: 10.1016/j.jss.2024.01.029. Epub 2024 Feb 9.
The risk of adverse outcomes after adrenal metastasectomy is not well defined. Knowledge of these risks is essential to guide patient counseling.
The 2015-2020 National Surgical Quality Improvement Program datasets were combined. Patients who underwent adrenalectomy for secondary adrenal malignancy (SM) and benign nonfunctional (BNF) adrenal neoplasms were identified; BNF neoplasms were chosen as a comparison as functional neoplasms can contribute to comorbidity. Patients who had additional surgery at the time of adrenalectomy were excluded. Patient demographics, comorbidities, perioperative factors, and outcomes were compared between groups. Multivariable logistic regression analysis was performed.
Of 3496 adrenalectomy patients, 332 had SM and 3164 had BNF neoplasms. Patients with SM were older (65 versus 54 y) and more often had chronic obstructive pulmonary disease (7.5% versus 4.4%), chronic steroid use (10.5% versus 3.8%), and bleeding disorders (4.5% versus 2.2%) than patients with BNF, respectively (P < 0.01 for all). Laparoscopic adrenalectomy was the most common operative approach for both groups (74.7% versus 88.3%). Rates of mortality, morbidity, reoperation, readmission, and nonhome discharge did not differ significantly between groups. Patients with SM had higher rates of postoperative bleeding than patients with BNF (6.3% versus 2.6%, P < 0.001). This persisted on multivariable regression analysis that adjusted for demographics, comorbidities, and operative approach (odds ratio 2.34, 95% confidence interval 1.19-4.64).
Adrenalectomy for SM is associated with an increased risk of postoperative bleeding compared to adrenalectomy for BNF adrenal neoplasms. Patients with SM that meet criteria for adrenal metastasectomy should be counseled appropriately.
肾上腺转移瘤切除术的不良结果风险尚未明确。了解这些风险对于指导患者咨询至关重要。
合并了 2015 年至 2020 年国家手术质量改进计划数据集。确定了因继发性肾上腺恶性肿瘤(SM)和良性无功能(BNF)肾上腺肿瘤而行肾上腺切除术的患者;选择 BNF 肿瘤作为对照,因为功能性肿瘤可能导致合并症。排除在肾上腺切除术时进行其他手术的患者。比较两组患者的人口统计学、合并症、围手术期因素和结局。进行多变量逻辑回归分析。
在 3496 例肾上腺切除术患者中,332 例患有 SM,3164 例患有 BNF 肿瘤。SM 患者年龄较大(65 岁 vs 54 岁),更常患有慢性阻塞性肺疾病(7.5% vs 4.4%)、慢性类固醇使用(10.5% vs 3.8%)和出血性疾病(4.5% vs 2.2%)(均 P < 0.01)。腹腔镜肾上腺切除术是两组最常见的手术方法(74.7% vs 88.3%)。两组患者的死亡率、发病率、再次手术、再入院和非家庭出院率均无显著差异。SM 患者术后出血率高于 BNF 患者(6.3% vs 2.6%,P < 0.001)。多变量回归分析调整了人口统计学、合并症和手术方法后,这一结果仍然存在(比值比 2.34,95%置信区间 1.19-4.64)。
与肾上腺切除 BNF 肿瘤相比,SM 的肾上腺切除术与术后出血风险增加相关。符合肾上腺转移瘤切除术标准的 SM 患者应适当咨询。